FHL-201

FHL-201 is a **preclinical small-molecule neurodegeneration program** being developed by Forest Hills Business Association for **Alzheimer's disease, Parkinson's disease, and multiple sclerosis**. Publicly available pipeline information does not disclose a specific molecular target, but preclinical summaries indicate a proposed mechanism centered on **neuronal protection**, **lysosomal biogenesis-mediated clearance of pathogenic molecules**, and **attenuation of brain inflammation**. Based on the available company pipeline description, FHL-201 appears to be an investigational new chemical entity intended to modify pathogenic processes common to multiple neurodegenerative and neuroinflammatory disorders.